Navigation Links
YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
Date:11/11/2009

a shareholders to vote on this transaction is scheduled to occur in January 2010.

    Nimotuzumab

    Nimotuzumab is currently being evaluated in 32 Phase II and III clinical
trials, 11 of which are being conducted by YM's majority owned subsidiary,
CIMYM BioSciences Inc., or its licensees.

    -   Daiichi Sankyo Co., Ltd., CIMYM's licensee for nimotuzumab in Japan,
        and YM's licensee in Korea, Kuhnil Pharmaceutical Co., are currently
        collaborating on a randomized, open-label Phase II trial evaluating
        nimotuzumab plus irinotecan compared to irinotecan alone in patients
        with advanced or recurrent gastric cancer refractory to 5-FU-
        containing regimens which is reportedly expected to complete
        recruitment in calendar 2009. Daiichi Sankyo is also conducting a
        Phase II trial in first-line NSCLC for which completion of
        recruitment is reportedly expected in the first half of 2010.

    -   YM initiated randomized, double-blind Phase II, trials in patients
        with brain metastases from non-small cell lung cancer (NSCLC) and in
        NSCLC patients ineligible for radical chemotherapy. Recruitment
        commenced in Canada in March 2009 for palliative NSCLC and in
        September for the brain metastases trial. A Phase II, second-line,
        single-arm trial in children with progressive diffuse intrinsic
        pontine glioma (DIPG) is ongoing at multiple sites in the US, Canada,
        and Israel.

    -   Oncoscience AG (OSAG), CIMYM's licensee for Europe, reported
        completion of recruitment in a single-arm, Phase III trial of
        nimotuzumab as first-line therapy for DIPG in August 2007, and the
        preliminary data from this trial that was released at ASCO in 2008
        was expanded on at the annual international pediatric oncology forum,
        SIOP, held in Sao Paulo, Brazil in October 2009. OSAG advises that,
        based on the data it plans to submit a Pediatr
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)...  Axovant Sciences Ltd. (NYSE:  AXON), a leading ... dementia, today announced that the company will host ... p.m. EDT following its presentation of RVT-101 clinical ... (AAIC). The event will include ... Lawrence Friedhoff , Chief Development Officer, will present ...
(Date:7/1/2015)... ... , ... A newly launched business plan contest will ask startup companies from ... life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small and ... of expert mentorship from a senior industry figure drawn from the Pistoia Alliance membership. ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that ... in Philadelphia, PA. , The presentation took place on Tuesday, June 16 ... for the development of APX3330 for the treatment of pancreatic cancer. A copy ...
(Date:7/1/2015)... 2015  UCB, a multinational biopharmaceutical company, and ... in designing, transforming, and running intelligent business operations, ... of their close collaboration in driving transformation that ... services (GBS) finance organization. The Aecus ... work together effectively to embrace the innovative promise ...
Breaking Biology Technology:Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5
... Iowa Patricia Thiel of Iowa State University and the Ames ... of coasters to the middle and a trinket box to the ... lots of little things." So Thiel grabbed the smaller things and ... box. "Nature wants one big thing all together, like this." ...
... 2010 Cannabis Science, Inc. (OTC Bulletin Board: ... pharmaceutical cannabis products announced today that regardless of the ... electoral issues throughout the country, it is apparent that ... more important than ever, as the demand for the ...
... Inc. (NYSE Amex: PIP ), a biodefense ... announced today that the Company was awarded four separate ... Project, enacted as part of the Patient Protection and ... is a benefit targeted to small business therapeutic discovery ...
Cached Biology Technology:Iowa State, Ames Laboratory scientists advance the understanding of the big getting bigger 2Proposition 19 Decision Prompts Cannabis Science to Anticipate Increased Demand for its Pharmaceutical Products for Critical Ailments and Begin the Formal Application Process for FDA Clinical Trials Immediately 2Proposition 19 Decision Prompts Cannabis Science to Anticipate Increased Demand for its Pharmaceutical Products for Critical Ailments and Begin the Formal Application Process for FDA Clinical Trials Immediately 3PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000 2PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000 3
(Date:6/30/2015)... -- Genisphere announced Tom Bliss ... develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss comes ... of the last 25 years in leadership positions at ... & Johnson. Tom started his career in Investment Banking, ... He graduated from Dartmouth College with a BA in ...
(Date:6/25/2015)... SALT LAKE CITY , June 25, 2015 /PRNewswire/ ... the first steps toward a healthier, happier life. That,s ... app is designed to do. The cutting-edge, portable health ... and offers real-life solutions to help improve your lifestyle ... Sellers Association awards dinner and gala Wednesday night, USANA,s ...
(Date:6/24/2015)... Calif. , June 24, 2015  Synaptics ... of human interface solutions, today announced that Sharp ... to provide secure authentication for its latest flagship ... reached more than 200 million shipments of its ... Sharp reinforces Synaptics, strength, scalability and leadership in ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... Lymphoma Protected by SPAK Silencing A group led ... of the protein SPAK may contribute to B-cell lymphoma development. ... issue of the American Journal of Pathology . ... system cancers. Epigenetic changes, such as DNA hypermethylation, may ...
... Consortium (PGSC), an international team of scientists from industry ... sequence of the potato genome with the help of ... horticulture in the College of Agriculture and Life Sciences ... potato variety that accelerated the development of a blueprint ...
... 2009Using clever chemistry, a Scripps Research team has pinpointed ... the progression of the devastating disease Friedreich,s ataxia in ... findings, developed in collaboration with scientists from Repligen Corporation, ... human clinical trials, which will be a welcome event ...
Cached Biology News:Tips from the American Journal of Pathology 2Tips from the American Journal of Pathology 3Tips from the American Journal of Pathology 4Tips from the American Journal of Pathology 5Draft potato genome based on unique potato variety 2Mechanism for potential Friedreich's ataxia drug uncovered 2Mechanism for potential Friedreich's ataxia drug uncovered 3